Pet Diabetes Care Market Report 2026

The pet diabetes care market size has grown strongly in recent years. It will grow from $2.4 billion in 2025 to $2.63 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to rising prevalence of diabetes in companion animals, introduction of standard insulin therapies for pets, growth in veterinary clinic networks, advancements in diagnostic tools for pet diabetes, increasing pet ownership.

The pet diabetes care market size is expected to see strong growth in the next few years. It will grow to $3.8 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to development of smart insulin delivery devices, expansion of home-based monitoring solutions, rising adoption of telemedicine platforms, increasing investment in veterinary endocrinology research, growing availability of species-specific oral medications. Major trends in the forecast period include increasing adoption of insulin therapy in pets, growth of at-home glucose monitoring for animals, rising awareness of diabetes management in companion animals, integration of telemedicine for pet diabetes care, development of species-specific oral hypoglycemic drugs.

The rising demand for pet insurance is expected to drive the growth of the pet diabetes care market in the coming years. Pet insurance provides financial protection that covers a portion of veterinary costs, helping pet owners manage expenses associated with their pets’ healthcare needs. The adoption of pet insurance is increasing as veterinary treatment costs rise, prompting owners to seek financial safeguards to manage unexpected medical expenses and ensure timely care for their pets. Pet diabetes care supports pet insurance by enabling early diagnosis and ongoing management, which reduces emergency complications and high treatment costs, leading to more predictable and sustainable insurance claims. For example, in April 2025, according to the North American Pet Health Insurance Association (NAPHIA), a US-based pet health insurance trade organization, the number of insured pets in North America increased to 7.03 million in 2024, up from 6.25 million in 2023 (a 12.2% rise), reflecting rapidly growing demand for pet insurance as owners seek financial protection against rising veterinary expenses. Therefore, the growing demand for pet insurance is driving the expansion of the pet diabetes care market.

Leading players in the pet diabetes care market are focusing on technological innovations, such as the Petrackr diabetes monitoring device, to provide reliable services to customers. The Petrackr diabetes monitoring device is a veterinary blood glucometer designed for monitoring diabetes in cats and dogs. For example, in May 2023, Universal Biosensors Inc., an Australia-based biosensor company, launched the Petrackr device. It delivers blood glucose test results within seconds and is easy for both pet owners and veterinary clinicians to use. The device is compatible with the Petrackr app, which allows users to conveniently record, monitor, and report results.

In July 2024, Dechra Limited, a UK-based global veterinary pharmaceuticals and animal health company providing therapeutic products and services for companion and food-producing animals, acquired the long-acting veterinary insulin programs from Akston Biosciences Corporation for an undisclosed amount. This acquisition enabled Dechra to expand its portfolio of pet diabetes care solutions by securing intellectual property and development rights to advanced insulin therapies aimed at improving glucose management in diabetic dogs and cats, thereby strengthening its position in companion animal metabolic disease treatment and future product commercialization. Akston Biosciences Corporation is a US-based biotherapeutics company with developmental programs focused on innovative long-acting insulin therapies for canine and feline diabetes.

Major companies operating in the pet diabetes care market are C.H. Boehringer Sohn AG & Co. KG, Becton Dickinson and Company, Merck & Co Inc., Zoetis Inc., Trividia Health Inc., Allison Medical Inc., UltiMed Inc., Apotex Inc., Henry Schein VET GmbH, Medtrust Holdings Inc., i-SENS Inc., Taidoc Technology Corp., Covetrus Inc., ALR Technologies Inc., Vet Innovations Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, AgaMatrix Inc., Ascensia Diabetes Care Holdings AG, Bayer AG, Dexcom Inc., LifeScan Inc., Medtronic PLC, Novo Nordisk A/S, Sanofi S.A., Senseonics Holdings Inc., Tandem Diabetes Care Inc., Terumo Corporation, Animas Corporation, Insulet Corporation, Roche Diabetes Care Inc.

North America was the largest region in the pet diabetes care market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pet diabetes care market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pet diabetes care market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pet diabetes care market by increasing the cost of imported insulin, glucose monitoring devices, and oral hypoglycemic agents, affecting primarily North America, Europe, and parts of Asia-Pacific. Segments like insulin therapy and glucose monitoring devices are most affected due to reliance on specialized imports. Positive impacts include the promotion of domestic manufacturing of diabetes care devices and medications, reducing dependency on foreign supply chains and stimulating local innovation.

The pet diabetes care market research report is one of a series of new reports that provides pet diabetes care market statistics, including pet diabetes care industry global market size, regional shares, competitors with a pet diabetes care market share, detailed pet diabetes care market segments, market trends and opportunities, and any further data you may need to thrive in the pet diabetes care industry. This pet diabetes care market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pet diabetes care addresses diabetes in pets, a condition that can lead to additional health issues such as heart disease, pancreatitis, urinary tract infections, kidney disease, and skin infections. Diabetes in pets arises from insufficient insulin production, its complete absence, or improper utilization, hindering the conversion of food into energy within their bodies.

The primary drug types within pet diabetes care comprise insulin therapy and oral medication. Insulin therapy aims to elevate peripheral glucose intake while reducing hepatic glucose synthesis, thereby regulating blood glucose levels in pets. Devices utilized for pet diabetes care encompass glucose monitoring devices and insulin delivery systems. These care measures cater to various animals such as canines, felines, and other species, implemented across veterinary clinics, home care settings, and veterinary hospitals.

The pet diabetes care market includes revenues earned by entities by insulin therapy and insulin delivery devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.